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EDITORIAL 
 
The role of thymosin-β4 in kidney disease 
 
Abstract 
Therapies which modulate inflammation and fibrosis have the potential to reduce the 
morbidity and mortality associated with chronic kidney disease. A promising avenue may be 
manipulating thymosin-β4, a naturally-occurring peptide which is the major G-actin 
sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. 
Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. In 
this editorial, we outline the evidence that thymosin-β4 may also have therapeutic benefit in 
chronic kidney disease. 
 
Keywords: Ac-SDKP, fibrosis, inflammation, kidney disease, thymosin-β4 
 
Introduction 
Over the last decade an epidemic of chronic kidney disease (CKD) has occurred, linked to 
increased obesity, hypertension and diabetes. Current treatment strategies control known 
risk-factors through pharmacological inhibitors and lifestyle changes but new therapies are 
urgently required. Regardless of the origin, the progression to CKD is accompanied by 
inflammation, fibrosis, extracellular matrix accumulation and tubular atrophy. Therefore, 
treatments which modulate these pathophysiological processes have the potential to reduce 
the morbidity and mortality associated with CKD. 
 
Thymosin-4 is a low molecular weight naturally-occurring peptide and the major G-actin–
sequestering protein in mammalian cells. Thymosin-4 regulates actin filament assembly 
and disassembly in a dynamic balance with the actin-binding competitor profilin and the 
depolymerisation factor cofilin [1, 2]. In addition, thymosin-β4 is able to form a complex with 
PINCH-1 and integrin-linked kinase both of which are necessary for cell migration and 
survival [3]. Thymosin-β4 can also bind to stabilin-2, a membrane receptor involved in the 
engulfment of apoptotic cells [4]. The ability of thymosin-β4 to regulate cell movement and 
turnover has led to studies showing it can stimulate coronary vasculogenesis and 
angiogenesis [5] and regulate inflammation and fibrosis in mouse models of lung, heart and 
cornea injury [6-8]. Thymosin-4 derivatives have similar properties. Thymosin-4 sulfoxide 
is anti-inflammatory [9], whilst the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-
SDKP; generated by thymosin-4 cleavage mediated by the enzyme prolyl oligopeptidase) is 
able to reduce fibrosis in animal disease models [10-12].  
 
Thymosin-β4 expression in developing, healthy adult and diseased kidneys 
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In the mouse kidney, thymosin-4 transcripts can be detected from embryonic day 12 and 
increase throughout development until 7 days after birth [13]. In embryonic day 18 mouse 
kidneys thymosin-β4 is localised in the interstitium surrounding developing tubules and in 
differentiating glomeruli as assessed by in-situ hybridisation [13]. Thymosin-β4 levels are 
lower in the adult kidney with gene expression restricted to collecting ducts and glomeruli in 
8 week old mouse kidneys [13]. Strong expression occurs in podocytes, the specialised 
epithelia of the glomerulus [13], a finding supported by profiling studies in adult mice 
identifying genes enriched in podocytes compared with the kidney cortex [14]. In contrast 
with these murine studies, immunohistochemisty of human fetal and adult kidneys have 
failed to detect thymosin-β4 protein in glomeruli [14] and further investigations are require to 
reconcile this discrepancy. 
 
A proteomic study using the rat remnant kidney model provided the first evidence implicating 
thymosin-β4 in the progression of CKD [15]. The investigators performed unilateral 
nephrectomy of the right kidney and ligation of the branches of the left renal artery resulting 
in 5/6 renal ablation. The reduction in renal mass led to compensatory growth of the 
remaining nephrons resulting in glomerulosclerosis and interstitial fibrosis. Using laser 
capture microdissection, sclerotic and non-sclerotic glomeruli were isolated from the remnant 
kidney as well as normal glomeruli from the nephrectomised kidney [16]. Proteomic analysis 
found that thymosin-β4 expression levels were significantly increased three fold in sclerotic 
versus normal glomeruli and localised predominately to endothelial cells [16]. Subsequent 
studies also demonstrated increased thymosin-β4 levels in macrophages, myofibroblasts 
and tubular epithelia in the unilateral ureteral obstruction (UUO) model, where the ureter is 
ligated leading to a rapid reduction in renal blood flow and glomerular filtration rate in the 
obstructed kidney and subsequent inflammation and fibrosis [12]. These findings of raised 
thymosin-β4 in CKD provide a rationale that modulating thymosin-β4 levels could be a 
promising therapeutic approach for renal disease.  
 
Exogenous thymosin-β4 and Ac-SDKP as therapeutic agents for kidney disease 
The therapeutic potential of thymosin-4 in patients is currently being assessed in several 
clinical trials for wound healing and cardiac repair [2]. However, to-date, there have only 
been two studies administering exogenous thymosin-β4 in animal models of renal disease, 
one in UUO and the other one in diabetic nephropathy. Administration of thymosin-β4 at a 
dose of 150 µg/day intraperitoneally did not alter the early phases of inflammation and 
fibrosis following UUO as examined five days after the surgical procedure [12]. However, by 
day 14 thymosin-β4 reduced fibrosis as assessed by Sirius red staining, but still had no 
effect on renal inflammation [12]. The authors began to explore the potential molecular 
mechanisms and found thymosin-β4 administration reduced plasminogen activator inhibitor-
1 (PAI-1) expression and transforming growth factor-β1 signalling, both of which are 
important pro-fibrotic pathways in CKD. Interestingly, when thymosin-β4 was then 
administered to PAI-1 knock-out mice that had also undergone UUO there was no 
improvement in either the early or late phases of disease progression. This finding indicated 
that changes in PAI-1 expression could be an important mechanism underlying the actions 
of thymosin-β4 in the UUO model.  
 
The second study [17] examined the therapeutic potential of thymosin-β4 in diabetic 
nephropathy, one of the leading causes of end-stage renal disease worldwide using a model 
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of type 2 diabetes mellitus, KK Cg-Ay/J mice. Twelve week old mice were treated daily with 
thymosin-β4 (100 ng/10 g/day intraperitoneally) or saline for three months. Thymosin-β4 
treatment improved renal function as shown by a reduction in the albumin to creatinine ratio 
and attenuated the renal pathological changes in KK Cg-Ay/J mice. However, the 
mechanisms that mediated these effects were not investigated; thymosin-β4 also improved 
hyperglycemia in KK Cg-Ay/J mice compared with saline controls and this may be the 
primary reason for the improvement in renal function and structure seen in this study. 
 
The N-terminal tetrapeptide Ac-SDKP has been more extensively studied in CKD. Cavasin 
and colleagues [18] showed that decreasing basal levels of Ac-SDKP in the mouse kidney 
by administrating an oral prolyl oligopeptidase inhibitor (S17092, 40 mg/kg/day) increased 
renal fibrosis and promoted glomerulosclerosis [18]. Other investigators have demonstrated 
beneficial effects of exogenous Ac-SDKP in CKD animal models. In the mouse UUO model, 
Ac-SDKP treatment (1.6 mg/kg/day) via osmotic minipumps decreased fibrosis at both early 
and late time-points [12] as evidenced by significant decreases in fibronectin, collagen I, 
PAI-1, TGF-β1 signalling and reduced numbers of renal macrophages and myofibroblasts. 
Similar findings were observed in a rat UUO model using a lower dose (400 µg/kg/day) of 
Ac-SDKP [19]. Two weeks after UUO, Ac-SDKP reduced fibrosis in the kidney as well as 
decreasing the number of macrophages. This was accompanied by a reduction in the renal 
expression of α-smooth muscle actin, monocyte chemoattractant protein-1 (MCP-1) and 
TGF-β1 [19]. A set of elegant studies using prophylactic and interventional experimental 
protocols examined the effect of exogenous Ac-SDKP (800 µg/kg/day) or vehicle 
administration in rat remnant kidneys [20]. In both protocols Ac-SDKP improved albuminuria, 
glomerular filtration rate, macrophage infiltration, glomerulosclerosis and renal collagen 
content [20]. In addition, these investigators found that Ac-SDKP reversed the loss of 
nephrin, a molecule critical for the integrity of the glomerular filtration barrier, seen in 
remnant kidneys providing a potential mechanism by which Ac-SDKP may elicit its 
therapeutic benefit in this animal model [20]. Ac-SDKP is also renoprotective in hypertensive 
mice [21]. In deoxycorticosterone acetate-salt hypertensive mice, Ac-SDKP treatment (800 
µg/kg/day) for three months improved glomerular matrix expansion, inflammation, fibrosis 
and albuminuria [21]. These effects were not due to an effect of Ac-SDKP in blood pressure 
which was unaltered. 
 
Ac-SDKP has also been shown to be beneficial in experimental diabetic nephropathy [11]. 
Ten week old male db/db mice were administered either 1 mg/kg/day of Ac-SDKP or 
balanced salt solution and examined 8 weeks later [11]. Ac-SDKP treatment did not alter 
hyperglycaemia, blood pressure or peripheral erythrocyte number but prevented the 
pathological increase in glomerular surface area, mesangial matrix expansion, and 
overproduction of extracellular matrix proteins compared with db/db mice administered 
balanced salt solution [11]. Ac-SDKP therapy also reduced plasma creatinine levels, but not 
albumin excretion compared with db/db mice treated with balanced salt solution [11]. The 
improvement in renal histology and function in db/db mice following Ac-SDKP treatment was 
accompanied by diminished TGF-β signalling within glomeruli [11]. Ac-SDKP treatment has 
also been tested in a rat model of type 1 diabetes induced by streptozotocin [10]. Eight 
weeks after streptozotocin injection, rats were provided with Ac-SDKP at a dose of 1 
mg/kg/day for two months delivered by osmotic minipump [10]. Ac-SDKP administration 
improved fibrosis in diabetic rats and reversed diabetes-induced loss of nephrin. Despite 
these molecular and structural changes, Ac-SDKP did not alter renal function with no 
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improvement in albuminuria observed [10]. This discrepancy may be due to the fact that Ac-
SDKP treatment was started too late after the induction of diabetes and further early 
intervention studies should be performed to address this issue.  
 
In another study [22] Omata and colleagues examined the therapeutic potential of Ac-SDKP 
in a rat model of glomerulonephritis. A preventive strategy was taken and Ac-SDKP 
(1mg/kg/day) administered by osmotic minipump two weeks after the induction of 
glomerulonephritis for one month. Ac-SDKP treatment ameliorated disease progression as 
demonstrated by reduced proteinuria, blood urea nitrogen, plasma creatinine, 
glomerulosclerosis and interstitial fibrosis compared with the rats administered saline [22]. 
Ac-SDKP treatment diminished TGF-β signalling in the kidney shown by reduced Smad2 
phosphorylation and increased Smad7 expression [22]. The renal expression of pro-
inflammatory genes (intercellular adhesion molecule 1, interleukin-1β, MCP-1 and tumor 
necrosis factor-α) were reduced by Ac-SDKP treatment along with the accumulation of 
macrophages in both the glomerulus and the tubulointerstitium [22]. Interestingly, Ac-SDKP 
did not alter the total number of peripheral leukocytes suggesting that the main effect of Ac-
SDKP was on monocyte infiltration into the kidney [22]. 
 
In conclusion, the progression of CKD involves inflammation and fibrosis; processes that can 
be modulated by thymosin-β4. The studies conducted so far have shown promising results 
for the therapeutic potential of thymosin-β4 in CKD. However more work is required to 
investigate the role of endogenous thymosin-β4 in the kidney, define the optimal therapeutic 
strategy using thymosin-β4 and its derivatives in different disease scenarios and identify the 
mechanisms that mediate the therapeutic effects of thymosin-β4 in CKD. These studies 
would strengthen the possibility of using thymosin-β4 as a novel treatment to reduce the 
morbidity and mortality associated with CKD. 
 
Expert Opinion 
The studies presented suggest that thymosin-β4 and its breakdown product Ac-SDKP could 
be a promising therapeutic avenue to reduce the morbidity and mortality associated with 
CKD. Further pre-clinical studies are required particularly using thymosin-β4 to determine 
optimal therapeutic doses and timing of treatment in different disease scenarios such as 
glomerulonephritis and remnant kidneys. There is also a need to compare the effectiveness 
of thymosin-β4 versus its derivatives for the treatment of kidney disease in animal models. 
This has been done for UUO [12] and these studies demonstrated that Ac-SDKP acts faster 
and reduces more disease parameters. To-date, there have been no studies examining the 
effect of thymosin-4 sulfoxide in CKD. 
 
Most of the studies to-date indicate that the benefits of thymosin-β4 and Ac-SDKP are due to 
reduced renal macrophage number and the attenuation of fibrosis, possibly via the 
modulation of TGF-β signalling. However, we do not yet understand how thymosin-β4 
precisely affects peripheral macrophages and resident kidney cells. Another area of interest 
could be potential effects on the endothelium which plays a key contribution to the 
progression of CKD [23]. 
 
Despite the studies demonstrating the therapeutic potential of thymosin-β4 and Ac-SDKP in 
experimental kidney disease, the functional role of endogenous thymosin-β4 in the kidney is 
completely unknown. Given the high expression of thymosin-β4 in podocytes and the role of 
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thymosin-β4 in regulating actin filament assembly, it could be postulated that thymosin-β4 
may play a role in regulating podocyte shape which could contribute to the integrity of the 
glomerular filtration barrier. Studies using transgenic mice lacking thymosin-β4 in specific 
cell types in the kidney will provide important insights into understanding the role of 
endogenous thymosin-β4 in the normal and diseased kidney. 
 
The studies described in this review have focused on using animal models to elucidate the 
role of thymosin-β4 and Ac-SDKP in the kidney and its relative levels in health and renal 
disease. Some studies have also shown that plasma Ac-SDKP is increased in CKD patients 
and further enhanced in those individuals also treated with angiotensin converting enzyme 
(ACE) inhibitors [24, 25]. These findings have been attributed to the impaired clearance of 
Ac-SDKP due to the decline in glomerular function in CKD [22] and the prevention of Ac-
SDKP degradation which normally occurs through the actions of ACE [26]. There is currently 
no human data available on the circulating or kidney levels of thymosin-β4 in patients with 
CKD and these studies should be undertaken in the future. 
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